Can You Really Own a Piece of a Clinical-Stage Biotech?

Final Chance: Cytonics’ Reg A+ Raise Closes August 27th; $3.00/share until then.

Here’s a question most biotech investors don’t get to ask themselves:

“Can I own a piece of a clinical-stage biotech… before the institutions show up?”

With Cytonics? Yes. 100%. Right now. And only until August 27th.

That’s when Cytonics’ Reg A+ round officially closes; it’s the final opportunity to invest at the $3.00/share price before potential future rounds at higher valuations and very different terms.

If you’ve ever said, “I wish I got in earlier”... this is earlier.


Why This Moment Is Rare

Most biotech deals work like this:

1. Closed rooms.
2. VC term sheets.
3. Institutional control.
4. You hear about it at the IPO… after the big upside is gone.

Cytonics said: Not this time.

Instead, they:

• Raised $25M+ with zero VC funding
• Built a clean cap table with a single class of stock
• Opened the doors to 7,000+ individual investors
• Completed Phase 1 clinical trials
• And created CYT-108, a biologic drug that could become the first-ever disease-modifying treatment for osteoarthritis

This isn’t theoretical. This is a company in motion, and you can still get in for now.


14 Days Left. Here’s What’s at Stake:

• Own shares in a clinical-stage biotech with Phase 1 success
• Lock in the $3.00/share valuation before the round closes
• Get the same terms as the top investors
• Be part of a company backed by science, not hype
• Join 7,000+ investors reshaping how biotech gets built

This isn’t just your opportunity to invest, it’s your opportunity to own the future of osteoarthritis treatment before it changes everything.


Final Countdown: Raise Closes August 27th at 11:59 PM

Invest today, final days to secure your shares. Only 14 days left to invest at $3.00/share. Join 7,000+ investors before the window closes. Secure your stake in the next generation of OA treatment.

Final days to secure your shares before August 27th